NDA 021232 · Swedish Orphan
Orfadin
Nitisinone · Oral · 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 17, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Jan 18, 2002
Approved uses
2
Original approval plus efficacy supplements
Registered trials
15
3 Phase 3, 0 recruiting
FAERS reports
820
649 serious, 146 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 30, 2021.
ORFADIN ® is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. ORFADIN is a hydroxy-phenylpyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. ( 1 )
Mechanism: Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with HT-1, nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 1, 2017 Supplement 20 · Efficacy OrphanLabelLetter
- Jan 18, 2002 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
4 products under this application
- ORFADIN · NITISINONE 20MG · CAPSULE, ORAL · Prescription · TE AB
- ORFADIN · NITISINONE 5MG · CAPSULE, ORAL · Prescription · TE AB
- ORFADIN · NITISINONE 10MG · CAPSULE, ORAL · Prescription · TE AB
- ORFADIN · NITISINONE 2MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Nitisinone" as an intervention, any sponsor and status, largest first.
- Suitability of Nitisinone in Alkaptonuria 2Pivotal-lookingStatus unknown
University of LiverpoolAcademic, hospital or other
NCT01916382 · 140 participants (planned) · Start Apr 2014 · Primary completion Feb 2016
Drug: Nitisinone · For: Alkaptonuria
Sites: Liverpool, United Kingdom
University of LiverpoolAcademic, hospital or other
NCT01828463 · 40 participants · Start May 2013 · Primary completion Oct 2013
Drug: Nitisinone · For: Alkaptonuria
Sites: Liverpool, United Kingdom
National Human Genome Research Institute (NHGRI)NIH
NCT00107783 · 40 participants · Start Jan 2005 · Primary completion Apr 2009
Drug: Nitisinone (NTBC) · For: Alkaptonuria
Sites: Bethesda, Maryland
Swedish Orphan BiovitrumIndustry
NCT03103568 · 36 participants · Start Mar 28, 2017 · Primary completion Jun 10, 2017
Drug: Nitisinone in Arm A; Tolbutamide and 4 more · For: Drug Drug Interaction
Sites: Berlin, Germany
University of FloridaAcademic, hospital or other
NCT00031161 · 30 participants (planned) · Start Sep 2001
Drug: Nitisinone (NTBC); Dichloroacetate · For: Acidosis, Lactic; Chronic Disease
Sites: Gainesville, Florida
Cycle Pharmaceuticals Ltd.Industry
NCT02750709 · 24 participants · Start Oct 2015 · Primary completion Dec 2015
Drug: Nitisinone; Nitisinone 10 mg Tablet High Compritol and 1 more · For: Hereditary Tyrosinemia, Type I
Sites: Bloemfontein, South Africa
- Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)Completed
Cycle Pharmaceuticals Ltd.Industry
NCT02750345 · 24 participants · Start Mar 2016 · Primary completion May 2016
Drug: Nitisinone; Nitisinone Baked Tablet and 1 more · For: Hereditary Tyrosinemia, Type I
Sites: Bloemfontein, South Africa
Cycle Pharmaceuticals Ltd.Industry
NCT02750332 · 20 participants · Start Nov 2015 · Primary completion Dec 2015
Drug: Nitisinone · For: Hereditary Tyrosinemia, Type I
Sites: Bloemfontein, South Africa
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- amino acid level increased128
- liver transplant117
- hepatocellular carcinoma61
- alpha 1 foetoprotein increased52
- treatment noncompliance49
- cataract47
- hepatic failure44
- hepatic cirrhosis37
- death35
- lenticular opacities34
- succinylacetone increased33
- vomiting33
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 5 |
| 2006 | 11 |
| 2007 | 7 |
| 2008 | 14 |
| 2009 | 18 |
| 2010 | 20 |
| 2011 | 28 |
| 2012 | 37 |
| 2013 | 14 |
| 2014 | 12 |
| 2015 | 30 |
| 2016 | 51 |
| 2017 | 69 |
| 2018 | 99 |
| 2019 | 129 |
| 2020 | 112 |
| 2021 | 40 |
| 2022 | 51 |
| 2023 | 19 |
| 2024 | 18 |
| 2025 | 16 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Orfadin (Nitisinone)
2024 spending
$243K
Beneficiaries
n/a
49 claims
Per beneficiary
n/a
$111.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $111,688 |
| 2021 | $334,339 |
| 2022 | $416,260 |
| 2023 | $317,274 |
| 2024 | $242,773 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of Nitisinone for patients with alkaptonuria: A systematic review with metanalysis.
Mayrink FD, Dorneles G, da Silva IM, et al. · Mol Genet Metab 2025 · Systematic Review, Meta-Analysis
- Patient-reported outcomes and functional assessments of patients with Alkaptonuria in a 3-year Nitisinone treatment trial.
Spears KR, Rossignol F, Perry MB, et al. · Mol Genet Metab 2024 · Randomized Controlled Trial, Research Support, N.I.H., Intramural
- A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.
Introne WJ, Perry MB, Troendle J, et al. · Mol Genet Metab 2011 · Randomized Controlled Trial, Research Support, N.I.H., Intramural
- Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone.
Imrich R, Sedláková J, Úlehlová M, et al. · RMD Open 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
Geppert J, Stinton C, Freeman K, et al. · Orphanet J Rare Dis 2017 · Systematic Review
- Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial.
Ooi N, Cooper IR, Norman B, et al. · Cells 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Swedish Orphan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.